Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation.
Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation.
复制标题
在重度抑郁症和慢性炎症患者中补充eicosapentaenoic酸后，循环抗炎和促脂质介质循环抗炎和促脂质介质的剂量和时间依赖性增加。
DOI：
10.1016/j.plefa.2020.102219
复制
发表时间：
2021-01
期刊：
影响因子：
--
通讯作者：
Rapaport MH
中科院分区：
文献类型：
--
作者：
Lamon-Fava S;So J;Mischoulon D;Ziegler TR;Dunlop BW;Kinkead B;Schettler PJ;Nierenberg AA;Felger JC;Maddipati KR;Fava M;Rapaport MH
补充二十碳五烯酸（EPA）是与慢性低度炎症相关的重度抑郁症（MDD）的有效治疗选择。EPA是称为消退素（resolvins，Rv）的专门促消退脂质介质（pro-resolving lipid mediator，SPM）的前体，其在炎症消退中起重要作用。本研究的目的是评估不同剂量的EPA对MDD患者EPA代谢物和SPM血浆浓度的影响。在一项双中心研究中，61名体重指数>25 kg/m2且血清高敏C反应蛋白≥3 μg/mL的MDD患者入选了一项为期12周的随机试验，比较EPA 1、2和4 g/d与安慰剂。在基线和治疗结束时，通过液相色谱/质谱法测量42名研究完成者的血浆EPA（mol%）和SPM（pg/mL）。在12周的治疗期间，安慰剂组的血浆EPA和SPM浓度没有变化。在所有EPA补充组中，血浆EPA和EPA衍生的代谢物显著且剂量依赖性地增加。从第4周至第12周，4 g/d EPA剂量组的RvE 1 -3前体18-羟基二十碳五烯酸（18-HEPE）的增加显著大于其他剂量组。在所有治疗组中均未检测到RvE 1，而在基线和治疗后均在半数受试者中检测到RvE 2，并呈剂量依赖性增加。RvE 3仅在补充后检测到，呈剂量依赖性。在所有EPA组中观察到血浆花生四烯酸（AA）相对于基线显著降低。这与4 g/d组中AA衍生SPM脂氧素B4（LXB 4）的增加形成对比。我们的研究结果显示，EPA 4 g/d补充剂在增加血浆EPA和18-HEPE水平方面具有强大的作用，并与RvE 2 -3和LXB 4水平的改善转化相关。
Eicosapentaenoic acid (EPA) supplementation is an effective treatment option in major depressive disorder (MDD) associated with chronic low-grade inflammation. EPA is the precursor of specialized pro-resolving lipid mediators (SPMs) termed resolvins (Rv), that serve important roles in the resolution of inflammation. The objective of this study was to assess the effects of different doses of EPA on plasma concentrations of EPA metabolites and SPMs in MDD patients. In a 2-site study, 61 MDD patients with body mass index >25 kg/m2 and serum high-sensitivity C-reactive protein ≥3 μg/mL were enrolled in a 12-week randomized trial comparing EPA 1, 2, and 4 g/d to placebo. Plasma EPA (mol%) and SPMs (pg/mL) were measured in 42 study completers at baseline and at the end of treatment by liquid chromatography/mass spectrometry. Plasma EPA and SPM concentrations did not change in the placebo group during 12 weeks of treatment. Plasma EPA and EPA-derived metabolites increased significantly and dose-dependently in all EPA supplementation arms. The increase in 18-hydroxyeicosapentaenoic acid (18-HEPE), the precursor of RvE1–3, was significantly greater with the 4 g/d EPA dose than the other doses from week 4 to 12. RvE1 was undetected in all treatment groups, while RvE2 was detected in half of the subjects both at baseline and after treatment, with dose-dependent increases. RvE3 was detected only after supplementation, dose-dependently. A significant reduction in plasma arachidonic acid (AA), relative to baseline, was observed in all EPA arms. This was in contrast with an increase in AA-derived SPM lipoxin B4 (LXB4) in the 4 g/d arm. Our results show a robust effect of EPA 4 g/d supplementation in increasing plasma EPA and 18-HEPE levels, associated with improved conversion to RvE2–3, and LXB4 levels.
登录
查看更多内容
DOI：
10.1074/jbc.m112.340612
发表时间：
2012-03-23
期刊：
The Journal of biological chemistry
影响因子：
--
作者：
Isobe Y;Arita M;Matsueda S;Iwamoto R;Fujihara T;Nakanishi H;Taguchi R;Masuda K;Sasaki K;Urabe D;Inoue M;Arai H
通讯作者：
Arai H
DOI：
10.2174/187152806776383125
发表时间：
2006-04-01
期刊：
Inflammation & Allergy Drug Targets
影响因子：
--
作者：
Parkinson, John F.
通讯作者：
Parkinson, John F.
影响因子：
6.5
作者：
Fischer, Robert;Konkel, Anne;Schunck, Wolf-Hagen
通讯作者：
Schunck, Wolf-Hagen
影响因子：
32.4
作者：
Buckley, Christopher D.;Gilroy, Derek W.;Serhan, Charles N.
通讯作者：
Serhan, Charles N.
DOI：
10.1073/pnas.0334211100
发表时间：
2003-02-18
影响因子：
11.1
作者：
Bagga, D;Wang, L;Reddy, ST
通讯作者：
Reddy, ST